Neuroendocrine tumor diagnosis and management: 68                         Ga-DOTATATE PET/CT

Yasemin Sanli; Ishan Garg; Asha Kandathil; Tuba Kendi; Maria J. Baladron Zanetti; Serkan Kuyumcu; Rathan M. Subramaniam

doi:10.2214/AJR.18.19881

Neuroendocrine tumor diagnosis and management: ⁶⁸ Ga-DOTATATE PET/CT

Yasemin Sanli, Ishan Garg, Asha Kandathil, Tuba Kendi, Maria J. Baladron Zanetti, Serkan Kuyumcu, Rathan M. Subramaniam

Research output: Contribution to journal › Article › peer-review

121 Scopus citations

Abstract

OBJECTIVE. The purpose of this article is to provide a review of the use of ⁶⁸ Ga tet-raazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a functional imaging modality for assessment of well-differentiated neuroendocrine tumors (NETs). It has become the preferred imaging modality for initial diagnosis, selection of patients for peptide receptor radionuclide therapy, and localization of unknown primary tumors. The National Comprehensive Cancer Network guideline has added ⁶⁸ Ga-DOTATATE PET/CT as an appropriate test in the management of NETs. CONCLUSION. In combination with FDG PET/CT, ⁶⁸ Ga-DOTATATE PET/CT can noninvasively assess tumor heterogeneity, especially in G2 and G3 NETs, for personalized management of patients.

Original language	English (US)
Pages (from-to)	267-277
Number of pages	11
Journal	American Journal of Roentgenology
Volume	211
Issue number	2
DOIs	https://doi.org/10.2214/AJR.18.19881
State	Published - Aug 2018

Keywords

Ga-DOTATATE
Neuroendocrine tumor
PET/CT

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2214/AJR.18.19881

Cite this

@article{d01b6fc9a06d4f8d88a75b1122d39946,

title = "Neuroendocrine tumor diagnosis and management: 68 Ga-DOTATATE PET/CT",

abstract = " OBJECTIVE. The purpose of this article is to provide a review of the use of 68 Ga tet-raazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a functional imaging modality for assessment of well-differentiated neuroendocrine tumors (NETs). It has become the preferred imaging modality for initial diagnosis, selection of patients for peptide receptor radionuclide therapy, and localization of unknown primary tumors. The National Comprehensive Cancer Network guideline has added 68 Ga-DOTATATE PET/CT as an appropriate test in the management of NETs. CONCLUSION. In combination with FDG PET/CT, 68 Ga-DOTATATE PET/CT can noninvasively assess tumor heterogeneity, especially in G2 and G3 NETs, for personalized management of patients.",

keywords = "Ga-DOTATATE, Neuroendocrine tumor, PET/CT",

author = "Yasemin Sanli and Ishan Garg and Asha Kandathil and Tuba Kendi and {Baladron Zanetti}, {Maria J.} and Serkan Kuyumcu and Subramaniam, {Rathan M.}",

note = "Publisher Copyright: {\textcopyright} American Roentgen Ray Society.",

year = "2018",

month = aug,

doi = "10.2214/AJR.18.19881",

language = "English (US)",

volume = "211",

pages = "267--277",

journal = "American Journal of Roentgenology",

issn = "0361-803X",

publisher = "American Roentgen Ray Society",

number = "2",

}

TY - JOUR

T1 - Neuroendocrine tumor diagnosis and management

T2 - 68 Ga-DOTATATE PET/CT

AU - Sanli, Yasemin

AU - Garg, Ishan

AU - Kandathil, Asha

AU - Kendi, Tuba

AU - Baladron Zanetti, Maria J.

AU - Kuyumcu, Serkan

AU - Subramaniam, Rathan M.

N1 - Publisher Copyright: © American Roentgen Ray Society.

PY - 2018/8

Y1 - 2018/8

N2 - OBJECTIVE. The purpose of this article is to provide a review of the use of 68 Ga tet-raazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a functional imaging modality for assessment of well-differentiated neuroendocrine tumors (NETs). It has become the preferred imaging modality for initial diagnosis, selection of patients for peptide receptor radionuclide therapy, and localization of unknown primary tumors. The National Comprehensive Cancer Network guideline has added 68 Ga-DOTATATE PET/CT as an appropriate test in the management of NETs. CONCLUSION. In combination with FDG PET/CT, 68 Ga-DOTATATE PET/CT can noninvasively assess tumor heterogeneity, especially in G2 and G3 NETs, for personalized management of patients.

AB - OBJECTIVE. The purpose of this article is to provide a review of the use of 68 Ga tet-raazacyclododecanetetraacetic acid–DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a functional imaging modality for assessment of well-differentiated neuroendocrine tumors (NETs). It has become the preferred imaging modality for initial diagnosis, selection of patients for peptide receptor radionuclide therapy, and localization of unknown primary tumors. The National Comprehensive Cancer Network guideline has added 68 Ga-DOTATATE PET/CT as an appropriate test in the management of NETs. CONCLUSION. In combination with FDG PET/CT, 68 Ga-DOTATATE PET/CT can noninvasively assess tumor heterogeneity, especially in G2 and G3 NETs, for personalized management of patients.

KW - Ga-DOTATATE

KW - Neuroendocrine tumor

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=85052368332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052368332&partnerID=8YFLogxK

U2 - 10.2214/AJR.18.19881

DO - 10.2214/AJR.18.19881

M3 - Article

C2 - 29975116

AN - SCOPUS:85052368332

SN - 0361-803X

VL - 211

SP - 267

EP - 277

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

IS - 2

ER -